Navigation Links
TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping

SCOTTSDALE, Ariz. July 17, 2013 The Side-Out Foundation's breast cancer pilot study, led by the Translational Genomics Research Institute (TGen), Translational Drug Development (TD2) and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling.

Specifically, 52 percent of patients with advanced breast cancer received clinical benefit meaning their disease was controlled for a longer time when their cancer was treated based on addressing the abnormal proteins in their tumor, according to the study conducted at the Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and TGen.

Each patient's treatment was "personalized," meaning that the therapy they received was based on their individual tumor biology.

"This study demonstrates the feasibility of personalized cancer treatment, and shows that this approach merits further investigation in future studies," said Gayle Jameson, Nurse Practitioner at Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the study's Principal Investigator.

"The success of this pilot study will lead to a larger study and hopefully greater clinical benefit for more patients with advanced breast cancer," said Jameson, who presented the results of the study in June at the 2013 American Society of Clinical Oncology (ASCO) in Chicago.

Due to the overwhelmingly positive results, a new study incorporating additional technology for tumor analysis, Side-Out II, will open at the Virginia G. Piper Cancer Center Clinical Trials in the near future for patients with advanced breast cancer.

"The success of our pilot proof-of-concept study has established a firm launching pad for the upcoming Side-Out II study, which involves a more in-depth investigation of tumor biology with an expanded repertoire of tests to direct personalized treatment," said Dr. Jasgit Sachdev, M.D., a breast cancer specialist and Associate Professor at the Virginia G. Piper Cancer Center Clinical Trials.

"By showing the significant advantages of molecular profiling, this pilot study has enabled us to move forward with a project that should strengthen the evidence for using this approach in routine clinical care."

The recent pilot study built on previous studies by Scottsdale Healthcare and TGen that showed the value of guiding treatment based on molecular profiling, in which each patient's tumor was analyzed for protein abnormalities that may "drive" the cancer's growth. The results pointed investigators toward specific genetic changes that might be addressed by specific medications.

Beyond molecular profiling, the pilot study also included mapping proteomic pathways within the tumor tissue so each patient could receive a highly targeted regimen designed to impede their cancer growth.

All of the patients in the recent study had advanced breast cancer that had progressed following multiple previous chemotherapy treatments. Of the 25 patients, 13 received clinical benefit as a result of molecular profiling. For all 25 patients, the therapy selected based on their tumor analysis was different than what they would have received in their next planned treatment, if they had not participated in the study.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare was the lead site in the 2- year pilot study. In addition, patients in the study were treated at Virginia Cancer Specialists, US Oncology, in Fairfax, Vir.; and at Evergreen Hematology & Oncology in Spokane, Wash.

Translational Drug Development (TD2), a TGen company, managed the pilot clinical trial, and will also oversee the follow-on study, Side-Out II.

"This was an exciting study for TD2," said Linda Vocila, BSN, RN, Director of Clinical Operations at TD2 and co-author of the study. "It demonstrates that close collaboration between physicians and scientists leads to greater clinical benefit for patients with cancer."

Two labs analyzed tissue: the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University in Manassas, Vir.; and Caris Life Sciences in Phoenix.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. Connect the Doc Practitioners to Provide Healthcare Services at the 82nd Stanley Park Tennis Tournament
2. Instant California Health Insurance Quotes and Texas Health Insurance Quotes Now Available Online from ACE Healthcare
3. NEONI Participates in Healthcare Career Event at Cleveland Convention Center Grand Opening
4. PreCheck and HRsoft Partner to Offer Integrated Background Screening and Applicant Tracking for Healthcare Employers
5. Marion VA Medical Center Highlighted in Healthcare Equality Index 2013
6. Orriant is Showing Employers How Utilizing a Company Wellness Program and the New Federal Healthcare Extension Can Benefit Their Bottom Line
7. Online USA Doctors Provides Unique Alternative to Traditional Healthcare Plans
8. Medical Sensors Market Report Is Focused on Giving a Bird’s Eye-View of the Industry With Regards to Global Sensors Market in Healthcare – Report by MarketsandMarkets
9. Online USA Doctors Launches a Platform Where Patients Can Find Quick Answers to All Their Health Related Questions and Find Healthcare Information Online
10. Priceless & Necessary: Data Management in Financial & Healthcare Industries
11. NTC Texas Launches NTC Healthcare Website
Post Your Comments:
(Date:11/30/2015)... CHICAGO, IL November 30, 2015 (PRWEB) , ... ... ... SpeechCheck and Winscribe are pleased to announce their strategic partnership at ... speech recognition consultants, SpeechCheck, Inc., and Winscribe, global providers of cutting-edge dictation ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... 2016. In 2016, expected coding changes are likely to include new codes for ... It’s not easy to understand the effects of code changes in musculoskeletal, radiology ...
(Date:11/30/2015)... ... ... today announced the introduction of three Nightstick® brand LED traffic wands with an average retail ... NSP-1632 ), yellow ( NSP-1634 ) and blue ( NSP-1636 ), the SL-1600 series LED ... in blinking strobe mode using a fresh set of 3 AAA cells (included). , Built ...
(Date:11/29/2015)... FL (PRWEB) , ... November 30, 2015 , ... ... available today from the new company, Sublime Beauty NATURALS®. All products are available ... natural products, like essential oils, organic facial serums and USDA Certified Organic Sesame ...
(Date:11/29/2015)... ... November 29, 2015 , ... "I struggled for years with pain ... Mother and Wife would love to do, I missed. We moved back home from ... call Dr. Zaidan first. They have changed my life drastically. I love all of ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
(Date:11/30/2015)... 30, 2015 Cumberland Pharmaceuticals (CPIX), today announced that ... on December 3, 2015. TIME: 3:15p.m. ET ... ET LINK: --> DATE: ... --> --> ... are invited to ask the company questions in real-time - ...
(Date:11/30/2015)... Nuance Communications, Inc. (NASDAQ: NUAN ) and ... today jointly announced a new integrated set of clinical ... College of Radiology,s (ACR) Imaging 3.0™ tools to enable ... current and emerging value-based payment models . ... clinical decision support, radiology reporting and image sharing technology ...
Breaking Medicine Technology: